메뉴 건너뛰기
Inflammatory Bowel Diseases
Volumn 21, Issue 1, 2015, Pages E2-E3
Clinical remission as defined by the mayo score: Do we deceive ourselves?
Author keywords

[No Author keywords available]
Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; ENDOSCOPY; HEALING; HUMAN; LETTER; MAYO CLINIC SCORE; MUCOSAL HEALING; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SIGMOIDOSCOPY; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; COLITIS, ULCERATIVE; MEDICAL RESEARCH; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; SEVERITY OF ILLNESS INDEX; WOUND HEALING;
EID: 84925798687     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000293     Document Type: Letter
Times cited : (3)
References (6)
  • 1
    • 84905497874 scopus 로고    scopus 로고
    • A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: Recommendations and implications for future research
    • Samaan MA, Mosli MH, Sandborn WJ, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: Recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465-1471.
    • (2014) Inflamm Bowel Dis , vol.20 , pp. 1465-1471
    • Samaan, M.A.1    Mosli, M.H.2    Sandborn, W.J.3
  • 2
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 3
    • 84856163835 scopus 로고    scopus 로고
    • Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
    • Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.
    • (2012) Gastroenterology , vol.142 , pp. 257-265
    • Sandborn, W.J.1    Van Assche, G.2    Reinisch, W.3
  • 4
    • 84882769357 scopus 로고    scopus 로고
    • Vedolizumab as induction and maintenance therapy for ulcerative colitis
    • GEMINI 1 Study Group
    • Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
    • (2013) N Engl J Med , vol.369 , pp. 699-710
    • Feagan, B.G.1    Rutgeerts, P.2    Sands, B.E.3
  • 5
    • 84904857048 scopus 로고    scopus 로고
    • Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial
    • Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet. 2014;384: 309-318.
    • (2014) Lancet , vol.384 , pp. 309-318
    • Vermeire, S.1    O'Byrne, S.2    Keir, M.3
  • 6
    • 84901231807 scopus 로고    scopus 로고
    • Histologic remission: The ultimate therapeutic goal in ulcerative colitis?
    • Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014; 12:929-934.
    • (2014) Clin Gastroenterol Hepatol , vol.12 , pp. 929-934
    • Peyrin-Biroulet, L.1    Bressenot, A.2    Kampman, W.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.